Decoy20

What is Decoy20?

Decoy20 is a multi-targeted toll-like receptor (TLR) agonist that activates TLRs on immune cells including macrophages and plasmacytoid dendritic cells. This stimulation produces pro-inflammatory cytokines and upregulates co-stimulatory molecules, enhancing T- and B-cell responses and promoting immune-mediated tumor cell killing. It is studied in solid tumors including hepatocellular carcinoma, colorectal cancer, pancreatic adenocarcinoma, non-small cell lung cancer, head and neck squamous cell cancer, and urothelial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Other

Mechanism

Immune activation

Pathways

TLR signaling, innate immune activation, adaptive immune response, cytotoxic T-cell proliferation

Therapy area

Oncology

Developer

Indaptus Therapeutics, Inc (INDP)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CRC (Colorectal Cancer)HCC - Hepatocellular CarcinomaMSI-H CancerNSCLC Non-small Cell Lung CancerPancreatic AdenocarcinomaSolid Tumor, AdultSquamous Cell Cancer of the Head and NeckUC (Urothelial Cancer)

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05651022

Updated Oct 3, 2026. Something wrong or missing? Report it on the INDP page.